MAbxience will develop Synagis, AbbVie's biosimilar, together with the University of Utrecht

Industry news

March 10th 2016Industry News

The Global. Chemo Group's biosimilar medicines division, mAbxience, has announced that it will develop a biosimilar to the monoclonal antibody palivizumab, marketed by AbbVie as Synagis.

READ MORE

recently published

Post thumb
Informative breakfasts "Study on the market of biosimilar medicines in the National Health System in Spain"
March 18 2024
Post thumb
Horizon scanning
Jan 31 2024
Post thumb
Early Treatment: the role of biosimilars
18 2023 December
Post thumb
Study on the market for biosimilar medicines in the National Health System in Spain 2016-2022
18 2023 December

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE